{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:36:45Z","timestamp":1793759805601,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016288","name":"Kissei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recent trends in the treatment of primary immune thrombocytopenia (ITP) were investigated using a claims database that included data from 16,161 Japanese patients with ITP collected from April 2014 to August 2022. Of the 4144 adult patients analyzed, 1276 received corticosteroids. The mean and median durations of corticosteroid use were 115.31 and 41\u00a0days, respectively. The time to withdrawal of corticosteroids was significantly shorter in 2020 to 2021 than in 2015 to 2019. Additionally, the number of prescriptions for thrombopoietin receptor agonists increased from 2015 to 2021 and exceeded that of corticosteroids in 2021. While these results suggest a trend towards reduction in corticosteroid use in real-world settings in Japan, 12.00% of patients received a corticosteroid dose of\u2009\u2265\u200910\u00a0mg\/day at Week 12. Furthermore, 23.05% of patients continued to receive corticosteroids at Week 24, indicating that some patients were still receiving long-term corticosteroid treatment. The risk of adverse outcomes was significantly associated with corticosteroid use. In conclusion, new treatment options may lead to more sophisticated ITP management with less corticosteroid use, although further research and reconsideration of clinical practice guidelines is needed.<\/jats:p>","DOI":"10.1007\/s12185-024-03897-8","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T18:43:27Z","timestamp":1734029007000},"page":"363-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan"],"prefix":"10.1007","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-8667","authenticated-orcid":false,"given":"Hirokazu","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Terasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Iwayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kanenishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"3897_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","volume":"2015","author":"DM Arnold","year":"2015","unstructured":"Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Prog. 2015;2015:237\u201342.","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"key":"3897_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12185-019-02790-z","volume":"111","author":"H Kashiwagi","year":"2020","unstructured":"Kashiwagi H, Kuwana M, Hato T, Takafuta T, Fujimura K, Kurata Y, et al. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. Int J Hematol. 2020;111:329\u201351.","journal-title":"Int J Hematol"},{"key":"3897_CR3","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829\u201366.","journal-title":"Blood Adv"},{"key":"3897_CR4","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780\u2013817.","journal-title":"Blood Adv"},{"key":"3897_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2326-12-2","volume":"12","author":"TM Brown","year":"2012","unstructured":"Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012;12:2.","journal-title":"BMC Blood Disord"},{"key":"3897_CR6","volume-title":"In: StatPearls [Internet]","author":"M Yasir","year":"2023","unstructured":"Yasir M, Goyal A, Corticosteroid SS, Effects A. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"3897_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.clinthera.2008.08.005","volume":"30","author":"D Berti","year":"2008","unstructured":"Berti D, Moons P, Dobbels F, Deuson R, Janssens A, De Geest S. Impact of corticosteroid-related symptoms in patients with immune thrombocytopenic purpura: results of a survey of 985 patients. Clin Ther. 2008;30:1540\u201352.","journal-title":"Clin Ther"},{"key":"3897_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3897_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1046\/j.1365-2796.2003.01219.x","volume":"254","author":"P Vestergaard","year":"2003","unstructured":"Vestergaard P, Olsen ML, Paaske Johnsen S, Rejnmark L, S\u00f8rensen HT, Mosekilde L. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med. 2003;254:486\u201393.","journal-title":"J Intern Med"},{"key":"3897_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","volume":"173","author":"MD George","year":"2020","unstructured":"George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for serious infection with low-dose glucocorticoids in patients with Rheumatoid arthritis: a Cohort Study. Ann Intern Med. 2020;173:870\u20138.","journal-title":"Ann Intern Med"},{"key":"3897_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PROM.S140932","volume":"9","author":"P Trotter","year":"2018","unstructured":"Trotter P, Hill QA. Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Relat Outcome Meas. 2018;9:369\u201384.","journal-title":"Patient Relat Outcome Meas"},{"key":"3897_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-6-13","volume":"6","author":"SD Mathias","year":"2008","unstructured":"Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, et al. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes. 2008;6:13.","journal-title":"Health Qual Life Outcomes"},{"key":"3897_CR13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/medicina56120667","volume":"56","author":"DR Terrell","year":"2020","unstructured":"Terrell DR, Neunert CE, Cooper N, Heitink-Poll\u00e9 KM, Kruse C, Imbach P, et al. Immune thrombocytopenia (ITP): current limitations in patient management. Medicina (Kaunas). 2020;56:667.","journal-title":"Medicina (Kaunas)"},{"key":"3897_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027350","volume":"6","author":"AC Matzdorff","year":"2011","unstructured":"Matzdorff AC, Arnold G, Salama A, Ostermann H, Eberle S, Hummler S. Advances in ITP - therapy and quality of life - a patient survey. PLoS One. 2011;6: e27350.","journal-title":"PLoS One"},{"key":"3897_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12185-021-03149-z","volume":"114","author":"TF Wong","year":"2021","unstructured":"Wong TF, Majewska R, Tomiyama Y. Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids. Int J Hematol. 2021;114:152\u201363.","journal-title":"Int J Hematol"},{"key":"3897_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12185-011-0791-1","volume":"93","author":"Y Kurata","year":"2011","unstructured":"Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329\u201335.","journal-title":"Int J Hematol"},{"key":"3897_CR17","first-page":"190","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5:190\u20138.","journal-title":"JMA J"},{"key":"3897_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15:457\u201365.","journal-title":"Expert Opin Drug Saf"},{"key":"3897_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ajh.20571","volume":"81","author":"CJ Bidot","year":"2006","unstructured":"Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol. 2006;81:391\u20136.","journal-title":"Am J Hematol"},{"key":"3897_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1365-2141.2008.07228.x","volume":"142","author":"C Pierrot-Deseilligny Despujol","year":"2008","unstructured":"Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, Gouault M, Intrator L, Bierling P, et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol. 2008;142:638\u201343.","journal-title":"Br J Haematol"},{"key":"3897_CR21","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.semarthrit.2015.07.008","volume":"45","author":"B LaMoreaux","year":"2016","unstructured":"LaMoreaux B, Barbar-Smiley F, Ardoin S, Madhoun H. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist. Semin Arthritis Rheum. 2016;45:e10\u20132.","journal-title":"Semin Arthritis Rheum"},{"key":"3897_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100125","volume":"7","author":"S Van de Vondel","year":"2023","unstructured":"Van de Vondel S, Vandenbriele C, Gheysens G, Verhamme P, Janssens A. Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag. Res Pract Thromb Haemost. 2023;7: 100125.","journal-title":"Res Pract Thromb Haemost"},{"key":"3897_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000520438","volume":"145","author":"AR Mehta","year":"2022","unstructured":"Mehta AR, Kefela A, Toste C, Sweet D. Real-world use of fostamatinib in patients with immune thrombocytopenia and thrombotic risk. Acta Haematol. 2022;145:221\u20138.","journal-title":"Acta Haematol"},{"key":"3897_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0151-2019","volume":"29","author":"D Price","year":"2020","unstructured":"Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. Eur Respir Rev. 2020;29: 190151.","journal-title":"Eur Respir Rev"},{"key":"3897_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","volume":"13","author":"MA Amiche","year":"2018","unstructured":"Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM, et al. Impact of cumulative exposure to high-dose oral glucocorticoid on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos. 2018;13:30.","journal-title":"Arch Osteoporos"},{"key":"3897_CR26","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","volume":"97","author":"JE Portielje","year":"2001","unstructured":"Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549\u201354.","journal-title":"Blood"},{"key":"3897_CR27","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.3390\/jcm12206422","volume":"12","author":"ME Mingot-Castellano","year":"2023","unstructured":"Mingot-Castellano ME, Canaro Hirnyk M, S\u00e1nchez-Gonz\u00e1lez B, \u00c1lvarez-Rom\u00e1n MT, B\u00e1rez-Garc\u00eda A, Bernardo-Guti\u00e9rrez \u00c1, et al. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI). J Clin Med. 2023;12:6422.","journal-title":"J Clin Med"}],"updated-by":[{"DOI":"10.1007\/s12185-025-03931-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03897-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03897-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03897-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:42:43Z","timestamp":1740487363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03897-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3897"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03897-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-025-03931-3","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to retrospective open access order.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12185-025-03931-3","URL":"https:\/\/doi.org\/10.1007\/s12185-025-03931-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HK is a member of the Editorial Board in International Journal of Hematology, and has received honoraria from Kissei Pharmaceutical Co., Ltd., argenx Japan, Novartis Pharma K.K and Sysmex Corporation. IM, NT and KI are employees of Kissei Pharmaceutical Co., Ltd. YF and MK are employees of Ark Medical Solutions Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of MINS, a specified nonprofit corporation and was conducted in accordance with the principles of the Declaration of Helsinki. This study protocol was registered in UMIN Clinical Trials Registry (Trial Number: UMIN000052806).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived because of the anonymity of patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}